» Articles » PMID: 39982548

Nonoperative Management of Rectal Cancer: Is "Near-Complete" Response Safe to Surveil?

Abstract

Background: Nonoperative management of rectal cancer in patients who achieve near-complete response following total neoadjuvant therapy remains controversial and understudied.

Methods: This retrospective cohort study conducted at a tertiary National Cancer Institute-designated cancer center included patients with rectal cancer who initiated active surveillance after achieving near-complete response following induction radiotherapy and consolidation chemotherapy. Near-complete response was determined based on restaging endoluminal evaluation and pelvic magnetic resonance imaging. Time-to-event analyses were used to estimate regrowth-free, proctectomy-free, disease-free, and overall survival.

Results: Of 61 patients who achieved near-complete response and initiated nonoperative management between February 2017 and March 2024, 36 (59.0%) maintained organ preservation with a median follow-up of 27.1 (interquartile range [IQR] 17.4-37.4) months. Twenty-five patients (41.0%) developed local regrowth by a median of 5.7 (IQR 3.2-8.2) months. All regrowths occurred within 17.5 months of initial restaging. Twenty-one patients with regrowth underwent salvage proctectomy, of which 20 (95.2%) achieved R0 resection margins. Following salvage proctectomy, four patients (19.0%) developed local recurrence. Disease-free and overall survival 2 years from restaging were 79.2% (95% confidence interval [CI] 67.0-93.6) and 93.3% (95% CI 86.3-100), respectively. Overall survival was not significantly different between patients with versus without local regrowth (log-rank p = 0.09).

Conclusions: Nonoperative management achieves clinically significant organ preservation rates without compromising oncologic outcomes in patients with near-complete response to total neoadjuvant therapy. Active surveillance allows time for continued evolution of tumor response and may substantially expand organ preservation in a patient population who otherwise would undergo avoidable radical surgery.

Citing Articles

ASO Author Reflections: De-escalation of Rectal Cancer Management and Expansion of Nonoperative Surveillance Protocols.

Zivanov C, Chapman Jr W Ann Surg Oncol. 2025; .

PMID: 40080365 DOI: 10.1245/s10434-025-17127-w.

References
1.
Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Meershoek-Klein Kranenbarg E . Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3.... Lancet Oncol. 2020; 22(1):29-42. DOI: 10.1016/S1470-2045(20)30555-6. View

2.
Cercek A, Roxburgh C, Strombom P, Smith J, Temple L, Nash G . Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 2018; 4(6):e180071. PMC: 5885165. DOI: 10.1001/jamaoncol.2018.0071. View

3.
Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J . Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020; 3(12):e2030097. PMC: 7745099. DOI: 10.1001/jamanetworkopen.2020.30097. View

4.
Habr-Gama A, Perez R, Nadalin W, Sabbaga J, Ribeiro Jr U, Silva e Sousa Jr A . Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004; 240(4):711-7. PMC: 1356472. DOI: 10.1097/01.sla.0000141194.27992.32. View

5.
Habr-Gama A, Perez R, Proscurshim I, Gama-Rodrigues J . Complete clinical response after neoadjuvant chemoradiation for distal rectal cancer. Surg Oncol Clin N Am. 2010; 19(4):829-45. DOI: 10.1016/j.soc.2010.08.001. View